Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20878440 | 1.00 | TMPRSS2 (0.42) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL10120820 | 1.00 | TMPRSS2 (0.42) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL20078639 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL17712511 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL17712266 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL24975093 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| SCHEMBL17712509 | 0.95 | TMPRSS2 (0.44) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| Remdesivir SCHEMBL24494884 | 0.94 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| Remdesivir SCHEMBL22143154 | 0.94 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 | |
| Remdesivir SCHEMBL24611640 | 0.94 | TMPRSS2 (0.40) | TMPRSS2CYP3A4CYP2C9BTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885CYP3A4 772/4885CYP2C9 2974/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885CYP3A4 1145/4885CYP2C9 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.